Delivery Order SPE2DB24D1021-SPE2DB25FEVVN

Award Date 4/11/25
Potential Completion Date 4/14/25
Potential Value $7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $6,344.66, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Otezla 30 mg tablets, a medication used to treat certain medical conditions. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 18, 2025. It is not designated as a set-aside contract, indicating open competition....
This federal contract award, valued at $6,167.34, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OTEZLA 30 MG TABLET 60S, a pharmaceutical product, with a period of performance through December 13, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $18,112.42, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the supply of Otezla 30 mg tablets, a medication used to treat certain medical conditions. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 17, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the...
This federal contract award, valued at $13,019.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Otezla 30 mg tablets, a prescription medication used to treat certain medical conditions. The contract is a Firm Fixed Price Delivery Order, with a performance period extending through April 30, 2025. It is not designated as a set-aside contract, indicating open...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Otezla 30 mg tablets. The contract, valued at $6,984.12, is a delivery order with a firm fixed price and an ultimate completion date of March 1, 2024. The contract is not designated with a set-aside. It is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop...
This federal contract award, valued at $9,483.14, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of Otezla 30 mg tablets in 60-count packaging. The award is a delivery order under the company's Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which is valued at $999,999,999 and runs through November 2026. This IDC serves as a primary...
This federal contract award is a delivery order placed by the Defense Logistics Agency (DLA) with AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,386.78 firm fixed-price contract is for the delivery of OTEZLA 30 MG TABLET 60S, a prescription medication, with a completion date of May 21, 2025. The contract is not set aside and is part of AmerisourceBergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm-fixed price delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $37,614.64 contract is for the delivery of Otezla 30 mg tablets, a medication used to treat certain medical conditions. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical to supply a wide range of...
This federal contract award, valued at $23,710.69, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Otezla 30 mg tablets, a medication used to treat certain medical conditions. This is a firm fixed-price delivery order contract with an ultimate completion date of April 30, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,692.38 Firm Fixed Price delivery order is for the supply of Otezla 30 mg tablets, a medication used to treat certain medical conditions. The contract has an ultimate completion date of June 10, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
  • SPE2DB24D1021
    Indefinite Delivery Contract
  • SPE2DB24D1021-SPE2DB25FEVVN
    Delivery Order

This federal contract award, valued at $6,972.25, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Otezla 30 mg tablets, a medication used to treat certain medical conditions.

The contract is a Delivery Order issued under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 7/11/25, 9:52 AM